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Abstract
Objective—To provide a single source for the best available estimates of the US prevalence of
and number of individuals affected by osteoarthritis, polymyalgia rheumatica and giant cell
arteritis, gout, fibromyalgia, and carpal tunnel syndrome, as well as the symptoms of neck and
back pain. A companion article (part I) addresses additional conditions.
Methods—The National Arthritis Data Workgroup reviewed published analyses from available
national surveys, such as the National Health and Nutrition Examination Survey and the National
Health Interview Survey. Because data based on national population samples are unavailable for
most specific rheumatic conditions, we derived estimates from published studies of smaller,
defined populations. For specific conditions, the best available prevalence estimates were applied
to the corresponding 2005 US population estimates from the Census Bureau, to estimate the
number affected with each condition.
Results—We estimated that among US adults, nearly 27 million have clinical osteoarthritis (up
from the estimate of 21 million for 1995), 711,000 have polymyalgia rheumatica, 228,000 have
giant cell arteritis, up to 3.0 million have had self-reported gout in the past year (up from the
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estimate of 2.1 million for 1995), 5.0 million have fibromyalgia, 4–10 million have carpal tunnel
syndrome, 59 million have had low back pain in the past 3 months, and 30.1 million have had
neck pain in the past 3 months.
Conclusion—Estimates for many specific rheumatic conditions rely on a few, small studies of
uncertain generalizability to the US population. This report provides the best available prevalence
estimates for the US, but for most specific conditions more studies generalizable to the US or
addressing understudied populations are needed.
METHODS
The purpose of this study, definitions of general terminology, and methods used for
ascertaining the data and generating the estimates are described in the companion article (1).
RESULTS
Osteoarthritis (OA)
OA is the most common type of arthritis. We estimated prevalence for each of the most
commonly affected joints (knees, hips, and hands) as well as for overall OA.
Estimating the prevalence of OA is difficult because the structural changes of the disease
occur in most persons as they get older, but these changes may not be accompanied by
symptoms. Furthermore, prevalence estimates vary considerably depending on whether only
moderate and severe radiographic changes are counted or mild changes are also included.
Clinically defined OA—Study examiners characterize a person as having OA on the basis
of symptoms and physical examination findings. The National Health and Nutrition
Examination Survey I (NHANES I) (2) showed that 12.1% of the US population ages 25–74
years had clinically defined OA of some joint.
Radiographically defined OA—Generally, researchers grade radiographs according to
the Kellgren/Lawrence scale (3), which defines OA on the basis of the presence of
osteophytes (outgrowths of bone at the margin of the joint). We summarized prevalence data
primarily from 3 recent US population-based studies: the NHANES III, the Framingham
Osteoarthritis Study, and the Johnston County Osteoarthritis Project. In these studies,
participants had to appear in person to undergo radiographic testing, and the validity of the
estimates could be compromised if only individuals who had symptoms (instead of all
individuals) attended. High participation rates for radiography (>70%) in all 3 studies make
this unlikely.
In phase 2 of the NHANES III (1991–1994), prevalence of knee OA was assessed in adults
age ≥60 years; this was the only study to use non–weight-bearing radiographs, a method that
minimizes joint space narrowing evident with weight bearing (4). The Framingham
Osteoarthritis Study was a survey of knee and hand OA in ~2,400 adults age ≥26 years from
suburban Boston, Massachusetts (5,6). The Johnston County Osteoarthritis Project was a
study of hip and knee OA in ~3,000 African American and white adults age ≥45 years in a
rural county in North Carolina (7). The prevalence of knee OA in adults age ≥45 was 19.2%
in Framingham and 27.8% in Johnston County, and the prevalence among adults age ≥60
was 37.4% in the NHANES III (Table 1). The prevalence of hip OA was high (27.0%) in
Johnston County adults age ≥45, but in another US community-based study of 4,855 women
age ≥65 years, prevalence was found to be only 7.2% (8). In the latter study, hip OA was
defined based on individual features, but the discordance among study results leaves
uncertainty regarding to the prevalence of hip OA. The prevalence of hand OA in
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Framingham adults was 27.2% overall and reached ≥80% among older adults, but only a
minority of persons with radiographic OA have pain in these joints.
OA prevalence increased with age and affected the hands and knees of women more
frequently than men, especially in persons age ≥50 years. In Johnston County and in the
NHANES III, African Americans were more likely than whites to have radiographic knee
OA. A study of perimenopausal women in Michigan also demonstrated that African
Americans were more likely than whites to have radiographic knee and hand OA (9). In the
NHANES III, the prevalence of radiographic knee OA was significantly higher in non-
Hispanic African Americans than in non-Hispanic whites or Mexican Americans (52.4%,
36.2%, and 37.6%, respectively) (4). In Johnston County, the prevalence of radiographic hip
OA was comparable in African Americans and whites (10).
Symptomatic OA—Persons are considered to have symptomatic OA if they have frequent
pain in a joint and radiographic evidence of OA in that joint, although sometimes this pain
may not actually emanate from the arthritis seen on the radiograph. Most prevalence surveys
require that a person have pain in a joint on most days of a recent month, to meet the
definition for presence of symptoms.
The prevalence of symptomatic knee OA was 4.9% among adults age ≥26 years in the
Framingham study, 16.7% among adults age ≥45 in the Johnston County study, and 12.1%
among adults aged ≥60 in the NHANES III study (Table 2).
The prevalence of symptomatic hip OA was 9.2% among adults age ≥45 in the Johnston
County study. The prevalence was slightly higher among women than among men for both
of these outcomes (Table 2). The prevalence of symptomatic hand OA in the Framingham
subjects (6) was 6.8% overall and was especially high in older adults. Among individuals
age ≥71 years, prevalence was 26.2% in women and 13.4% in men.
Using the Framingham data on age/sex prevalence among persons age ≥26 years and the
corresponding 2005 population estimates from the Census Bureau, we estimated that
9,267,000 adults have symptomatic knee OA and 13,054,000 adults have symptomatic hand
OA. The generalizability of the Framingham estimates to the US population has not been
determined.
For estimating overall OA, we calculated weighted age/sex-specific prevalence estimates of
clinical arthritis for persons ages 25–74 from the NHANES I, the only published national
source of data on OA at multiple anatomic sites and the source we used in our 1998 report
(11). Using the corresponding 2005 population estimates from the Census Bureau and
additionally applying the NHANES I estimate for those ages 65–74 to the Census population
age ≥75 years, we estimated that 26.9 million adults age 25 and older have clinical OA of
some joint. Whether the 1971–1975 NHANES I estimates reflect the 2005 US population
prevalence is uncertain.
Polymyalgia rheumatica (PMR) and giant cell (temporal) arteritis (GCA)
PMR and GCA, two closely related syndromes that occur almost exclusively in persons age
≥50 years, appear to be much more common in whites than in other racial or ethnic groups
(12). In the US, prevalence is highest among persons of northern European descent (13,14).
The only population-based study of PMR and GCA in the US is from Olmsted County,
Minnesota, where the prevalences of PMR and GCA were derived from cumulative
incidence rates. GCA was diagnosed according to the American College of Rheumatology
(ACR) criteria (15). Among persons age ≥50 years in 2000, the prevalence of PMR was 739
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per 100,000 (95% confidence interval [95% CI] 674–808) (16) and the prevalence of GCA
was 278 per 100,000 (95% CI 192–268) (17). For each, the prevalence was higher in women
than in men and increased dramatically with age (for PMR, from 21 per 100,000 among
persons ages 50–54 years to 4,070 per 100,000 among those age ≥90 years) (Table 3).
In addition to these data, case series of PMR and GCA suggest that these conditions are
common throughout the US. In Europe, incidence rates in populations in the northern area of
the continent are similar to those of Olmsted County, Minnesota, whereas rates among
southern European populations are lower (18–21).
In summary, PMR is common in older adults. GCA, which is approximately one-third as
common as PMR, is the most common form of vasculitis in the population over 50 years of
age. Using the Olmsted County age/sex prevalence rates and the corresponding 2005
estimates from the Census Bureau, we estimated that 711,000 Americans have PMR and
228,000 have GCA. With the aging of the US population, these estimates are likely to
increase in coming years. These Olmsted County estimates are generalizable to the white US
population, but their generalizability to other racial/ethnic populations is uncertain.
Gout
Gout is an inflammatory arthritis that results from phagocytosis of monosodium urate
monohydrate crystals within the joint and is usually associated with an elevated
concentration of uric acid in the blood, i.e., hyperuricemia. Among criteria developed to
classify gout, the ACR criteria (22) have been used in recent epidemiologic studies (23,24).
Our previous National Arthritis Data Workgroup (NADW) report (11) reviewed the
population-based Tecumseh Community Health Study (25), the Framingham Heart Study
(26), and the Sudbury Study (27) (Table 4), all of which were relatively small studies of
gout conducted in confined geographic regions. All of these studies took place before the
ACR criteria were developed, the age populations included were not consistent among
studies.
The prevalence of gout also has been estimated using self-reported information from the
National Health Interview Survey (NHIS) and the NHANES (Table 4). Because these self-
reports were not verified, the data may produce an overestimate of prevalence. For example,
investigators in the Sudbury Study (27) could validate only 44% of self-reported cases using
Rome (28) or New York (29) criteria, and in a study of health professionals (23), only 70%
of cases could be validated by ACR criteria. However, in one study of physicians (24), it
was reported that 100% of self-reported cases could be validated by ACR criteria and
medical record review. In the most recent NHIS survey on gout (1996), the prevalence for
the 1-year period was 940 per 100,000 adults age ≥18 years in the US (30). Prevalence
increased with age, was higher in men than in women at all ages, and among those age ≥45
years was higher in African Americans than in whites.
One-year period prevalence estimates derived from the NHIS over time can be compared
directly because the instrument has not changed. In this survey, the presence of gout is
recorded if a respondent answers “yes” to the question, “Have you or any member of your
household had gout within the past year?” From 1969 to 1985 the prevalence more than
doubled, with the steepest increase occurring between 1969 and 1976 (30), but the increase
later slowed between 1992 and 1996 (840 and 940 per 100,000, respectively) (Table 4). In a
recent study from a US managed care population, the overall prevalence of gout or
hyperuricemia requiring a gout or urate-lowering medication increased by 80% from 1990 to
1999 (31); however, this increase may reflect treatment change.
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The lifetime prevalence estimate from the NHANES III (1988–1994) (32), based on the
question, “Has a doctor ever told you that you had gout?,” was 2,600 per 100,000 overall for
those age ≥20 years, with a low of 400 per 100,000 in adults ages 20–29 years and a peak of
8,000 per 100,000 in adults ages 70–79 years (Table 4). Gout was reported more often by
men than by women overall, but prevalence increased with age for both, especially among
women after menopause.
In summary, gout appears to be increasing in frequency. Using 1996 NHIS and NHANES
III age/sex prevalence data and the corresponding 2005 population estimates from the
Census Bureau, we estimated that 3.0 million adults age ≥18 years had gout in the past year,
and 6.1 million adults age ≥20 have ever had gout. Both are likely overestimates because
they are based on self-reported data.
Fibromyalgia
The 1990 ACR criteria for the classification of fibromyalgia require the presence of
widespread pain for at least 3 months and pain on palpation in at least 11 of 18 anatomic
sites (33). Despite its acceptance, a number of problems occur when the ACR criteria set is
used to define fibromyalgia in populations, leading to difficulties in estimating prevalence
(34–36). Also, fibromyalgia may be more common among persons with other medical
conditions (37), so prevalence estimates of primary fibromyalgia may be lower than
estimates that do not differentiate primary fibromyalgia from fibromyalgia secondary to
other disorders.
Wolfe et al conducted the only study of the prevalence of primary fibromyalgia in the US, in
Wichita, Kansas in 1993 (38). At the time of the study, the population of Wichita was ≥88%
white, different from that of the overall US population. From a random sample of 3,006
adults age ≥18 years, 193 individuals with chronic widespread pain were examined and 36
cases of ACR-defined fibromyalgia were confirmed. The overall prevalence among adults
was ≥2% (95% CI 1.4–2.7); prevalence was higher among women than among men (3.4%
versus 0.5%). In women, the prevalence of fibromyalgia rose sharply in middle age, to a
maximum of 7.4% in the 70–79-year age group, and then dropped off. Prevalence in men
similarly peaked in the eighth decade of life, but was only slightly more than 1% among
men in this age group. Fibromyalgia was associated with depressive and anxiety symptoms,
current and past depression, and a history of depression in the family. Other characteristic
symptoms, i.e., “pain all over,” subjective swelling, paresthesias, stiffness, sleep
disturbance, fatigue, and irritable bowel syndrome, were also associated with fibromyalgia
(38). Women experienced more of these associated symptoms than men (34). Other factors
associated with fibromyalgia included reduced income and education, higher rates of
divorce, and application for disability benefits (38).
Although no recent prevalence studies of fibromyalgia in the US have been published, a
population survey of 3,395 randomly selected adults (≥18 years of age) in Ontario, Canada
showed 100 cases of fibromyalgia, yielding an even higher overall age/sex-adjusted
prevalence of 3.3% (95% CI 3.2–3.4%) (4.9% in women and 1.6% in men) (39). As in the
US study, the prevalence of fibromyalgia in women rose with age, to a peak of 7.9% in the
55–64-year age group, and declined thereafter. The prevalence in men also increased with
age, and peaked at 2.5% in the 45–54-year age group.
Using the Wichita age/sex prevalence and the corresponding 2005 population estimates from
the Census Bureau, we estimated that ~5.0 million adults age ≥18 years have primary
fibromyalgia. The generalizability of the Wichita estimates to the US population is
uncertain.
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Carpal tunnel syndrome (CTS)
Because there is no gold standard for the diagnosis of CTS and no standard definition of the
syndrome, and because some cases can be transient, challenges arise in determining the
prevalence of this condition. The clinical examination findings associated with CTS have
sensitivities and specificities in the range of 45–80% (40). The typical location of symptoms
in the median nerve distribution has sensitivity and specificity in the range of 60–70%
(41,42). On median nerve conduction testing, >20% of asymptomatic individuals exhibit
abnormalities consistent with CTS (42,43).
The most well–accepted definitions of CTS involve combinations of symptom,
electrophysiologic, and physical examination findings. Three population-based prevalence
studies have been performed in Europe, involving a combination of history, physical
examination, and nerve conduction assessments. Atroshi and colleagues (44), in a Swedish
study, inquired about symptoms typical of CTS (40,42) and studied symptomatic and
asymptomatic subjects further by history-taking, physical examination, and nerve
conduction studies. They estimated the prevalence of symptoms typical of CTS, of
symptoms accompanied by examination findings indicative of CTS, of symptoms
accompanied by positive electrophysiologic results, and of symptoms accompanied by
positive findings on all tests. The prevalence of CTS was consistently higher in women than
in men, and rose with age. CTS prevalence ranged from 2% to 4% in men and 3% to 5% in
women, depending on the stringency of the case definition.
Ferry and colleagues (45) administered a hand symptom diagram (42) to a random
population sample in the UK. Persons with and persons without typical symptoms of CTS
underwent physical examination and electrophysiologic testing. The prevalence of positive
nerve conduction findings did not differ between subjects with typical CTS symptoms and
asymptomatic subjects. Thus, although the authors reported a prevalence of
electrophysiologic evidence of CTS on the order of 10%, it is difficult to draw conclusions
about the prevalence of symptomatic CTS.
In an earlier study, de Krom and colleagues (46) evaluated the prevalence of CTS in 715
persons from The Netherlands. Of the respondents, 1.6% had diagnosed CTS and 9% had
nocturnal finger paresthesias. The latter underwent neurologic and electrophysiologic
evaluation. The overall prevalence of CTS (either diagnosed or detected via this 2-stage
screening process) was 5.8% in women and 0.6% in men.
Studies using a combination of self-report, physical examination, and nerve conduction
testing have not been performed in the US. Tanaka et al analyzed data from the 1988 NHIS
(47). Respondents were asked if they had CTS. An estimated 1.55% of 170 million adults
(2.65 million) self-reported CTS. CTS was twice as common among women as among men
(47). The self-report nature of the case definition makes these data difficult to interpret.
In summary, the prevalence of electrophysiologically confirmed, symptomatic CTS, based
on studies conducted outside the US, is ~1–4% in men and 3–5% in women, with prevalence
increasing with age. Using these adult prevalence estimates and the corresponding 2005
population estimates from the Census Bureau, we estimated that 1–4 million men and 3–6
million women in the US have CTS.
Back and neck pain
Low back pain affects most adults at some time. Because back pain is rarely permanent,
terms such as incidence and prevalence may be ambiguous. Although neck pain is less
common than low back pain, it shares many similar characteristics. The thoracic spine’s
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mobility is limited by the rib cage, and is less often a cause of back pain except in
osteoporosis. Thus, the prevalence of thoracic spine pain is rarely reported.
Back pain is a symptom, not a disease. For many, a precise pathoanatomic diagnosis is
impossible (48,49). There is no definitive imaging or diagnostic test to determine its
prevalence. Investigators depend on patient self-report, and many patients have few
objective physical findings.
In epidemiologic surveys, back pain has been defined in many ways. These include counting
any episode of back pain, counting pain lasting a certain length of time, counting only
“severe” pain, or counting only pain that results in work disability. We focused on
population-based estimates of self-reported symptoms, separating neck and low back pain,
and attempting to distinguish reports of any back pain, frequent or persistent back pain, and
pain with symptoms of radiculopathy (nerve root irritation, usually manifesting as sciatica).
In the 2002 NHIS, respondents were asked whether they had low back pain or neck pain
during the past 3 months. Respondents were instructed to report pain that lasted a whole day
or longer (50). Approximately one-fourth of all adults in the US reported experiencing low
back pain in the past 3 months, and the prevalence of neck pain was approximately half that
estimate (Table 5). The prevalence was similar among men and women and among most
racial groups, with the exception of a high prevalence among American Indians and Alaskan
Natives, and a low prevalence among Asian Americans. Prevalence declined with increasing
levels of education.
From an analysis of the 1997 NHIS, it was estimated that 3.2% of all persons experienced
activity limitations due to chronic back conditions (51). Among the poor, activity limitation
was nearly 3 times more frequent than in middle- and high-income adults.
Although about half of adults report low back pain during a given year and about two-thirds
report low back pain at some time in their lives (52–60), only 15–21% of the adult
population reported frequent low back pain (56) and only 14% reported an episode of low
back pain lasting longer than 2 weeks at any time in their lives. Pain lasting beyond 3–6
months occurs in only 5–10% of patients with back pain. Approximately 1–2% of adults
report having received a diagnosis of a herniated disc.
Computed tomography and magnetic resonance imaging studies in small samples indicate
that disc degeneration, fractures, herniated discs, and spinal stenosis are all common among
asymptomatic persons (61,62). Thus, the prevalence of radiographic findings is substantially
different from the prevalence of clinically important symptoms.
In summary, back pain is common. The etiology is often unclear and classification is
controversial, but most episodes probably originate in muscles or ligaments, or are the
consequences of degenerative changes in the intervertebral discs and adjacent vertebrae.
These changes include osteoarthritic changes in the facet joints and similar degenerative
changes in and around the intervertebral discs. Back pain remains a leading cause of work
disability.
Using 2002 NHIS age-specific prevalence and the corresponding 2005 population estimates
from the Census Bureau, we estimated that 59.1 million adults age ≥18 years have had low
back pain “in the past 3 months.” Using the 1997 NHIS age-specific prevalence and the
corresponding 2005 population estimates from the Census Bureau, we estimated that 7.1
million adults age ≥18 have activity limitation due to chronic back conditions. Using the
same sources, we estimated that 30.1 million adults age ≥18 have had neck pain “in the past
3 months.”
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As discussed in the companion article (1), the burden of a chronic condition can be
measured in various ways. The NADW has chosen to focus on national disease prevalence
as an important measure of burden.
The prevalence of clinical osteoarthritis has grown to nearly 27 million, up from our
estimate for 1995 of 21 million (11), as would be expected for such a strongly age-related
disease. Gout appears to be increasing in frequency as well, with a 1-year prevalence of 3.0
million adults, a higher frequency than in the earlier study. These increases in such common
conditions suggest they will have a growing impact on the health care and public health
systems in the future, one that needs to be anticipated in order to provide the early diagnosis
and interventions that can help reduce that impact.
We have provided estimates of prevalence and numbers of persons affected for overall
arthritis and for selected rheumatic conditions and given a rough snapshot of current burden.
These estimates have been made by recognized disease experts using the best data available,
but, as noted in many of the sections, must be interpreted with several limitations in mind,
including those detailed in the companion report (1). Given the large and growing burden of
arthritis and other rheumatic conditions, we hope this work will inspire studies that better
address these gaps and limitations and provide a better understanding of the burden of these
conditions.
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Table 1
Prevalence of radiographic OA in the hands, knees, and hips, by age and sex, from population-based studies*
Anatomic site,
age, years Source (ref.)
% with mild, moderate,
or severe OA
Male Female Total
Hands, ≥26 Framingham OA study (6) 25.9 28.2 27.2
Knees†
    ≥26 Framingham OA study (5) 14.1 13.7 13.8
    ≥45 Framingham OA study (5) 18.6 19.3 19.2
    ≥45 Johnston County OA Project (7) 24.3 30.1 27.8
    ≥60 NHANES III (4) 31.2 42.1 37.4
Hips, ≥45 Johnston County OA Project (10) 25.7 26.9 27.0
*
Estimates represent prevalence per 100 persons age-standardized to the projected 2000 Census population (see ref. 63) except for National Health
and Nutrition Examination Survey III (NHANES III) estimates, which were adjusted to the 1980 Census population.
†
All data on radiographic knee osteoarthritis (OA) are based on anteroposterior radiographs and therefore capture only tibiofemoral OA. Inclusion
of patellofemoral imaging would probably yield higher prevalence estimates.
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Table 2
Prevalence of symptomatic OA (symptoms and radiographic changes of OA in the symptomatic joint) in the
hands, knees, and hips, by age and sex, from population-based studies*
Anatomic site,
age, years Source (ref.)
% with symptomatic OA
Male Female Total
Hands, ≥26 Framingham OA study (6) 3.8 9.2 6.8
Knees
    ≥26 Framingham OA study (5) 4.6 4.9 4.9
    ≥45 Framingham OA study (5) 5.9 7.2 6.7
    ≥45 Johnston County OA Project (7) 13.5 18.7 16.7
    ≥60 NHANES III (4) 10.0 13.6 12.1
Hips, ≥45 Johnston County OA Project (10) 8.7 9.3 9.2
*
Adjusted to the projected 2000 population age ≥18 years (see ref. 63) except for National Health and Nutrition Examination Survey III (NHANES
III) estimates, which were adjusted to the 1980 Census population. OA = osteoarthritis.























































































































































































































































































































































































Lawrence et al. Page 15
Table 4
Prevalence of gout in the United States*
Source and year of study/gout




    Tecumseh Community Health Study, 1960/“Rome” (25)† ≥20 720 480 ND
    Framingham Heart Study, 1964/arbitrary (26)‡ ≥42 (mean 58) 2,850 390 1,480
    Sudbury Study, 1972/Rome and New York (27) ≥15 660 100 370
National survey studies
    NHIS, 1988/self-report (1-year prevalence) (64)§ ≥18 ND ND 850
18–44 290 90 310
45–64 3,350 950 2,100
≥65 4,110 1,700 2,700
    NHIS, 1992/self-report (1-year prevalence) (65)§ ≥18 ND ND 840
18–44 440 30 380
45–64 2,630 810 1,680
≥65 4,410 1,820 2,900
    NHIS, 1996/self-report (1-year prevalence) (30)§ ≥18 ND ND 940
18–44 340 20 180
45–64 3,350 1,200 2,240
≥65 4,640 1,950 3,080
    NHANES III, 1988–1994/self-report (lifetime prevalence) (32)¶ ≥20 3,800 1,600 2,600
≥20–29 200 500 400
30–39 2,100 100 1,100
40–49 2,600 900 1,700
50–59 5,600 2,300 3,900
60–69 9,400 3,200 6,100
70–79 11,600 5,200 8,000
≥80 7,100 5,300 5,900
*
ND = no data; NHIS = National Health Interview Survey; NHANES III = National Health and Nutrition Examination Survey III.
†
“Rome” = Rome criteria used “insofar as possible.”
‡
Arbitrary = at least 2 of the following 3 features: a typical attack of arthritis, an attack of arthritis with a prompt response to colchicine therapy,
and/or hyperuricemia.
§
One-year prevalence of gout ascertained by the question, “Have you or any member of your household had gout within the past year?”
¶
Lifetime prevalence of gout ascertained by the question, “Has a doctor ever told you that you had gout?” Interviewers were instructed to
emphasize the word “doctor.” If the respondent stated that it was another health professional who gave the diagnosis of gout to him or her, the
answer was coded as “no.”
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